Progyny (PGNY) Cash & Equivalents (2018 - 2026)

Progyny (PGNY) has reported Cash & Equivalents for 9 consecutive years, with $152.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 15.19% year-over-year to $152.6 million in Q2 2026; TTM through Jun 2026 was $152.6 million, a 15.19% increase from a year earlier, with the FY2025 full-year figure at $112.2 million, down 30.85% from the prior year.
• Cash & Equivalents was $152.6 million for Q2 2026 at Progyny, up from $131.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $170.6 million in Q2 2023 and troughed at $38.8 million in Q1 2022.
• A 5-year average of $116.9 million and a median of $117.5 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 300.09% in 2023 and sank 44.33% in 2024, its largest moves.
• Over 5 years, Cash & Equivalents stood at $120.1 million in 2022, then slipped by 18.97% to $97.3 million in 2023, then surged by 66.82% to $162.3 million in 2024, then slumped by 30.85% to $112.2 million in 2025, then soared by 35.99% to $152.6 million in 2026.
• The last three Cash & Equivalents figures came in at $152.6 million (Q2 2026), $131.6 million (Q1 2026), and $112.2 million (Q4 2025), per Business Quant data.